Drugs / CHS-114
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06657144 | Apr 2025 → Jan 2028 expected | metastatic neoplasm | Coherus Oncology, Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT05635643 | Dec 2022 → Sep 2026 overdue | head and neck squamous cell carcinoma | Coherus Oncology, Inc. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 6
| Date | Issuer | Release |
|---|---|---|
| 2026-01-05 | Coherus Oncology, Inc. | Results Coherus Oncology Announces Publication in Molecular Cancer Therapeutics Highlighting the Strong Pharmacology of Investigational CCR8 Antibody Tagmokitug (CHS-114) coherus.com ↗
In the first-in-human clinical study, proof of mechanism is established with translational data showing tagmokitug administration leads to selective reductions in CCR8+ Tregs and not other T cell subsets in cancer patients. |
| 2025-11-07 | Coherus Oncology, Inc. | Results Coherus Oncology Presents at SITC Clinical Multiomic Biomarker Data for CHS-114, a Highly Selective anti-CCR8 Cytolytic Antibody coherus.com ↗
In on-treatment tumor biopsies, CHS‑114 depleted CCR8+ Tregs, but not CCR8- Tregs, and increased CD8+ T cells in the tumor microenvironment (TME), indicating TME remodeling for antitumor immune activation and establishing proof of mechanism. |
| 2025-04-28 | Coherus Oncology, Inc. | Results Coherus Presents Promising Early Clinical Data from Phase 1 Dose Expansion Study of CHS-114 in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma at AACR 2025 coherus.com ↗
The data showed a confirmed partial response in a heavily pretreated PD-1 refractory patient, a > 50% depletion in CCR8+ Treg, and an increase in CD8+ T cells, consistent with anti-tumor activity and demonstrating proof of mechanism. |
| 2024-05-23 | Coherus Oncology, Inc. | Results Coherus Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-chemokine receptor 8 (CCR8) Antibody, CHS-114, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting coherus.com ↗ |
| 2023-11-03 | Coherus Oncology, Inc. | Results Coherus Presents Data from Next-generation Immuno-oncology Programs at 38th Annual Meeting of Society for Immunotherapy of Cancer (SITC) coherus.com ↗
Anti-CCR8 antibody, CHS-114, depletes tumor-infiltrating Treg cells and activates NK cells in dissociated head and neck squamous cell carcinoma (HNSCC) tumors |
| 2023-09-27 | Coherus Oncology, Inc. | Results Coherus Announces Three Presentations at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) coherus.com ↗
Abstract #1354: Anti-CCR8 antibody SRF114 depletes tumor-infiltrating regulatory T cells in dissociated tumors from patients with head and neck squamous cell carcinoma |
All press releases naming this drug 8 releases
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CHS-114 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05635643 ↗ |
| Known as | Tagmokitug | “CHS-114 (Tagmokitug)” NCT06657144 ↗ |
| Action | Deplete | “CHS-114 selectively binds human CCR8 and potently kills CCR8 expressing cells by inducing antibody-dependent cellular cytotoxicity” PMID 41423415 ↗ May 2026 |
| Modality | Monoclonal antibody | “CHS-114 is a highly selective, afucosylated human anti-CCR8 monoclonal antibody” PMID 41423415 ↗ May 2026 |
| Route | Intravenous | “administered as an intravenous (IV) infusion” NCT06657144 ↗ |
| Target | CCR8 | “CHS-114 selectively binds human CCR8” PMID 41423415 ↗ May 2026 |